CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,144 enrolled
Drug / intervention
AZD1981 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01197794
NCT01197794Phase 2Completed

A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients

AstraZeneca·interventional·Posted Sep 9, 2010·Updated Nov 6, 2013

In Brief

A Phase 2 clinical trial evaluating AZD1981 and Placebo for Asthma Patients. Completed, enrolled 1,144 participants across 105 sites in 10 countries.

Detailed Summary

The study will assess the efficacy, safety and tolerability of AZD1981 compared to non-active compound in asthmatic patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma Patients
CountriesArgentina, Brazil, Japan, Mexico, Romania, Russia, Slovakia, South Africa, Ukraine, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 9, 2010
Enrollment StartOct 1, 2010
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.8 years ago

Interventions

AZD1981drug

AZD1981 twice daily

AZD1981drug

AZD1981 once daily

Placebodrug

Placebo to match AZD1981